Suven Life Sciences Limited (BOM:530239)
136.90
+1.65 (1.22%)
At close: Jan 22, 2026
Suven Life Sciences Revenue
Suven Life Sciences had revenue of 9.19M INR in the quarter ending September 30, 2025, a decrease of -64.27%. This brings the company's revenue in the last twelve months to 58.63M, down -30.33% year-over-year. In the fiscal year ending March 31, 2025, Suven Life Sciences had annual revenue of 66.56M, down -43.08%.
Revenue (ttm)
58.63M
Revenue Growth
-30.33%
P/S Ratio
517.97
Revenue / Employee
424.84K
Employees
138
Market Cap
30.37B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 66.56M | -50.37M | -43.08% |
| Mar 31, 2024 | 116.93M | -19.02M | -13.99% |
| Mar 31, 2023 | 135.95M | 16.44M | 13.76% |
| Mar 31, 2022 | 119.51M | -21.23M | -15.08% |
| Mar 31, 2021 | 140.73M | -6.32M | -4.30% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| IOL Chemicals and Pharmaceuticals | 21.70B |
| Neuland Laboratories | 15.33B |
| Shilpa Medicare | 13.43B |
| Bajaj HealthCare | 6.11B |
| Sudeep Pharma | 5.61B |
| NGL Fine-Chem | 4.08B |
| Infinium Pharmachem | 1.57B |
| Gujarat Themis Biosyn | 1.55B |
Suven Life Sciences News
- 6 weeks ago - Suven Life Sciences achieves 100% enrollment for Phase-2b Trial of Ropanicant for major depressive disorder - Business Upturn
- 1 year ago - Suven Life Sciences shares surge over 8% after clinical trial update - Business Upturn
- 1 year ago - Suven Life Sciences initiates Phase-1 clinical trial for SUVN-I6107 - Business Upturn
- 1 year ago - Suven Life Sciences reports positive Phase-2a results for Ropanicant in treating Major Depressive Disorder - Business Upturn
- 1 year ago - Suven Life Sciences announces FDA acceptance of Investigational New Drug - Business Upturn